{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0079495\nAge: 73\nGender: Male\nSample ID: P-0079495-T01-IM7\nGene Panel: IMPACT505\nCancer Type: Prostate Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 70.0%\n=============\nDNA Variants:\nB2M nan (nan) - in 86.00% of 87 reads\nBRCA2 c.5450del (p.S1817Ffs*23) - in 24.00% of 95 reads\nCREBBP c.2423_2424del (p.V808Gfs*23) - in 38.00% of 648 reads\nFAT1 c.203G>T (p.W68L) - in 33.00% of 238 reads\nMSH6 c.122C>G (p.S41C) - in 32.00% of 398 reads\nMYC c.130_132del (p.E44del) - in 6.00% of 1127 reads\nPIK3CB nan (nan) - in 12.00% of 375 reads\nPTEN c.33_34insTA (p.N12*) - in 26.00% of 92 reads\nSETDB1 c.3845G>C (p.G1282A) - in 32.00% of 445 reads\nSMARCA2 c.1259_1260delinsCG (p.R420P) - in 36.00% of 425 reads\nTP53 c.374C>T (p.T125M) - in 56.00% of 242 reads\nCNA Data:\nRECQL4 - High Level Amplification\nMYC - High Level Amplification\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}"
}